Mar 21 |
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
|
Mar 20 |
Bionomics First Half 2024 Earnings: AU$1.62 loss per share (vs AU$2.16 loss in 1H 2023)
|
Feb 22 |
Bionomics to Present at the 2024 BIO CEO & Investor Conference
|
Feb 5 |
10 Best Australian Stocks To Buy
|
Jan 22 |
Bionomics Provides a Review of 2023 and of 2024 Plans
|
Jan 5 |
Bionomics to Present at Biotech Showcase™ 2024
|
Dec 22 |
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals
|
Dec 6 |
Bionomics presents data on reliability of the Subjective Units of Distress Scale
|
Dec 6 |
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting
|
Oct 30 |
12 Best Stocks For Day Trading
|